Pancreatic ductal adenocarcinoma (PDAC) is expected to be the second cause of cancer death by 2022. For nearly 80% of patients, diagnosis occurs at an advanced, nonsurgical stage, making such patients incurable. Gemcitabine is still an important component in PDAC treatment and is most often used as a backbone to test new targeted therapies and there is, to date, no routine biomarker to predict its efficacy. Samples from a phase III randomized trial were used to develop through a large approach based on blood-based liquid biopsy, transcriptome profiling, and machine learning, a nine gene predictive signature for gemcitabine sensitivity. Patients with a positive test (41.6%) had a significantly longer progression free survival (PFS) (3.8 months vs. 1.9 months = 0.03) and a longer overall survival (OS) (14.5 months vs. 5.1, < 0.0001). In multivariate analyses, this signature was independently associated with PFS (HR = 0.5 (0.28-0.9) = 0.025) and OS (HR = 0.39 (0.21-0.7) = 0.002).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692046 | PMC |
| http://dx.doi.org/10.3390/cancers12113204 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.
Neurol Neuroimmunol Neuroinflamm
March 2025
Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), chitinase-3-like 1 (sCHI3L1), and the immune responses to the Epstein-Barr virus-encoded nuclear antigen 1 to current MS diagnostic criteria.
Methods: In this multicentric study, we selected patients from 2 prospective cohorts presenting a clinically isolated syndrome (CIS).
Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma.
An Acad Bras Cienc
January 2025
Universidade Federal de Pernambuco, Departamento de Histologia e Embriologia, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50760-420 Recife, PE, Brazil.
Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. The increase in the expression of these enzymes has been related to greater tumor aggressiveness. MMP-26 is expressed constitutively in the endometrium and some cancer cells of epithelial origin.
View Article and Find Full Text PDFPredicting the Propensity of Atrial Cardiopathy and Paroxysmal Atrial Fibrillation in Patients with Embolic Stroke of Undetermined Source (ESUS).
Arq Bras Cardiol
January 2025
Cardiovascular Medicine Department, Faculty of Medicine, Tanta University, Tanta - Egito.
Background: There is still a significant population of patients with embolic stroke of Undetermined Source (ESUS) whose specific attributable cause of the stroke remains unknown.
Objectives: Our research aimed to assess clinical, electrocardiogram, laboratory, and echocardiographic parameters that may predict the propensity of paroxysmal atrial fibrillation (PAF).
Methods: We enrolled seventy-five ESUS patients who were in sinus rhythm at the time of stroke diagnosis to undergo in-hospital 7-day Holter monitoring, testing for Pro-BNP, and a standard echocardiographic examination.
Retinopathy of prematurity: Accuracy of ROPScore and WINROP algorithms in a Brazilian population.
Arq Bras Oftalmol
January 2025
Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Purpose: To assess the sensitivity and specificity of the retinopathy of prematurity score (ROPScore) and weight, insulin-like growth factor-1, retinopathy of prematurity algorithm in predicting the risk of developing severe retinopathy of prematurity (prethreshold type 1) in a sample of preterm infants in Brazil.
Methods: Retrospective analysis of medical records of preterm infants (n=288) with birth weight of ≤1500 g and/or gestational age of 23-32 weeks in a neonatal unit in Southern Brazil from May 2013 to December 2020 (92 months).
Results: The incidence of confirmed severe retinopathy of prematurity was 6.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!